HCM - Outlook Healthier For Key Chinese Sector

• China’s leading biotechnology and other health care companies have continued to grow revenues rapidly over the past two years and are expected to see strong growth in the years to come.
• Recently, concerns over domestic regulation, increased domestic competition, US Food and Drug Administration (FDA) rejections of China-made medications, and delisting risks have led to a significant downdraft in the shares of China-based health care companies.
• Now could be an opportune time to add exposure to high-quality companies that we believe are currently selling at a discount.

For further details see: